Reply  by Raatikka, Marja et al.
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June 2, 2004:2147–51iterature, but then to perform a small validation study before
dopting a new technique with confidence.
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herapy of Recurrent Pericarditis
e read with interest the paper by Raatikka et al. (1) that gives us
useful piece of information regarding pericarditis in children.
he data are relevant, particularly regarding the good long-term
utcome, with no instance of constriction, in agreement with our
xperience in adults. We would like to comment on some
tatements regarding therapy. The authors in fact conclude that
orticosteroids, methotrexate, azathioprine, cyclosporine, and col-
hicine did not prevent recurrences. Should we conclude that no
rug is effective, so that no drug should be employed? We have
ublished case reports describing different experiences. A 14.5-
ear-old boy (2) previously treated with high-dose steroids, intra-
enous immunoglobulin, and indomethacin experienced an excel-
ent response when colchicine 1 mg was added, while slowly
apering steroids and continuing indomethacin. In another 12-
ear-old boy (3) who did not respond well to nonsteroidal
nti-inflammatory drugs (NSAIDs) and prednisone, the introduc-
ion of colchicine proved beneficial; thereafter, the patient pre-
ented with six relapses, each occurring 1 to 4 weeks after the
iscontinuation of colchicine on his own initiative. The excellent
tudy by Raatikka et al. (1), in our opinion, was not designed to
ssess the problem of therapy, with the interactions between
ifferent drugs, dosages, and combinations: we have to wait for
ore definitive studies specifically addressing therapy. Moreover,
e have to evaluate if efficacy of a drug means that it must work
fter discontinuing all the previous therapies (e.g., to stop steroids
nd NSAIDs and add de novo colchicine) or, probably more
isely, if a drug’s efficacy means that it works when added to a
revious active therapy (e.g., to add colchicine to steroids and
SAIDs).
In the meantime, even if it will be proved true that recurrent
ericarditis has a chronic course irrespective of the therapy given,
nd that the activity of the disease gradually “burns out” sponta-
eously, it remains necessary to use some drugs, the less toxic ones,
uring the acute phases. In our opinion, this is best accomplished mith a multidrug therapy including: 1) a very slow tapering of
teroids (months), similar to what is often done in many rheuma-
ologic conditions; 2) NSAIDs used at the recommended dosages;
nd 3) introduction of colchicine, if tolerated. In our experience,
his therapy greatly ameliorates the quality of life of these patients,
nd possibly may reduce the number of recurrences. We acknowl-
dge that it will be difficult to formally prove the efficacy of this
herapy in the framework of a randomized, controlled trial.
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EPLY
e appreciate the interest of Dr. Brucato and his colleagues in our
tudy on recurrent pericarditis in children and adolescents (1). We
gree that the treatment of this condition is often problematic and
rustrating. The goals of the therapy are to control the pain, to
revent tamponade, and to stop recurrences. In our series, threat-
ning tamponade was not encountered after first attacks and
ericardial effusion diminished in later relapses irrespective of the
iven therapy. Thus, the control of pain remains the main task in
herapy during a recurrence of the disease. This is possible in most
ases with nonsteroidal anti-inflammatory drugs (NSAIDs) in
ufficient doses, added with other pain killers if needed. Even
ecurrences with high C-reactive protein values usually settle down
ith such treatment within 7 to 10 days. It is tempting to use
orticosteroids as they are very effective in suppressing the pain and
n relieving the pericardial effusion. However, in our patients
teroid treatment tended to increase the number of relapses.
urther, the well-known side effects of corticosteroids are espe-
ially undesirable in growing children and adolescents. Therefore,
e would spare the corticosteroid treatment for the most severe
ases only.
Colchicine treatment for preventing relapses has raised consid-
rable expectations because of the good results published by Adler
t al. (2). Sadly, this treatment failed to prevent recurrences in all
our of our patients in whom colchicine was added to corticoste-
oid treatment. One possible reason for the contradicting results
ay lie in the different genetic characteristics of the study
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ericarditis. Clearly, there is a need for an international, random-
zed study to test the effectiveness of colchicine and other treat-
ents, for example, intrapericardial triamcinolone administration
ested by Maisch et al. (3). The evaluation of the effectiveness of
reatments is difficult on the basis of single cases, as the course of
ecurrent pericarditis is unpredictable although gradually “burning
ut.” The chronicity of the condition is exemplified by two of our
atients believed to be cured of the disease, but who after the
cceptance of our article have had new relapses after 9 and 11 years’
uiescence, respectively.
Similar to Dr. Brucato and his colleagues, we find it important
o use as nontoxic drugs as possible during the acute phases of
ericarditis. However, our experience in young patients does not
upport their recommendation of routine multidrug therapy in-
luding long-term corticosteroids, colchicine, and NSAIDs. In our
ands, mere NSAID treatment was in the long run at least as
ffective as the treatment with different immunosuppressive drugs.
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ime Course of the Interaction
etween Tadalafil and Nitrates
he Express Publication by Kloner et al. (1) on the interactions
etween nitrates and tadalafil should be of interest to all cardiol-
gists and physicians seeing patients with acute chest pain.
However, I have several questions: 1) What is the duration of
rectile dysfunction efficacy of tadalifil? The long half-life suggests
hat responsiveness to the drug may last 2 to 3 days; do we know
hether the blood pressure and heart rate effects of nitrates with
adalafil on board are concordant with the duration of improve-
ent in sexual function? 2) It is unclear whether there is a repeat
un-in of 7 days for both placebo and tadalafil after the cross-over,
hat is, is the second-half dosing the same as the first part of the
rotocol? 3) Why is the recommendation made to withhold
oncomitant use of a nitrate and tadalafil for 48 h when all data
obustly support no interaction at this time interval? 4) The palf-life of sildenafil, the gold standard phosphodiesterase 5
PDE5) inhibitor is not provided. This would be useful, including
he best estimate of its duration of its action, as well as the time
eriod during which there is a potentially hazardous interaction
etween this PD5 inhibitor and nitrates. 5) Is it possible that an
cute dosing interaction (no previous exposure for several days)
ith nitrates with sildenafil or tadalafil might induce a different
esponse to nitrates than after 5 to 6 consecutive half-lives of the
D5 inhibition? Thus, it may be that a form of tolerance to nitrate
emodynamic effects could develop within days in the vasculature,
ttenuating the decrease in blood pressure and increase in heart
ate after an individual has been taking a PD5 inhibitor for a
onsiderable amount of time, as in this experiment. The protocol
esign does not really mirror the way sildenafil and tadalafil are
sed in daily living. It would be useful to know if there are data
hat answer these questions.
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EPLY
e would like to thank Dr. Abrams for his questions regarding
ur study on the time course of the interaction between tadalafil
nd sublingual nitroglycerin (SL-NTG) (1). In response to ques-
ion 1 regarding the duration of efficacy: Since the publication of
he article (1), tadalafil, a phosphodiesterase 5 (PDE5) inhibitor,
as been approved by the Food and Drug Administration for the
reatment of erectile dysfunction (ED) (2). Tadalafil improves
rectile function in men with ED for up to 36 h after dosing (2,3).
herefore, the duration of efficacy of tadalafil for the treatment of
D for up to 36 h is similar to the time course of the interaction
f tadalafil with nitrates (i.e., the hemodynamic interaction be-
ween tadalafil and SL-NTG lasted 24 h but was not seen at 48 h
nd beyond).
In response to question 2 regarding study design: Our study was
randomized, placebo-controlled, double-blind, two-period,
ross-over, multicenter study (n  150). During treatment period
, subjects received seven consecutive daily doses of either tadalafil
20 mg) or placebo before SL-NTG administration. After a 10- to
1-day washout period, subjects were crossed over to the opposite
reatment (treatment period 2) and received seven consecutive
aily doses of either tadalafil or placebo before SL-NTG admin-
stration.
In response to question 3 regarding the recommendation to
ithhold nitrates for 48 h: In our study, SL-NTG (0.4 mg) was
dministered at 2, 4, 8, 24, 48, 72, and 96 h after the last dose of
adalafil 20 mg or placebo. Tadalafil augmented the blood
ressure-lowering effects of SL-NTG from 2 to 24 h post-dosing
